APP-13007 is under clinical development by Formosa Pharmaceuticals and currently in Phase III for Ocular Pain (Eye Pain). According to GlobalData, Phase III drugs for Ocular Pain (Eye Pain) have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how APP-13007’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
APP-13007 is under development for the treatment of post-operative inflammation and pain of the eye. The drug candidate is administered through ophthalmic route in the form of suspension. It is developed based on the Activus pure nanoparticle technology.
Formosa Pharmaceuticals overview
Formosa Pharmaceuticals is a biopharmaceutical business focused on ophthalmology, cancer, and anti-infectives at both the preclinical and clinical stages. The company is headquartered in Taipei City, Taiwan.
For a complete picture of APP-13007’s drug-specific PTSR and LoA scores, buy the report here.